| L - Antineoplastic and Immunomodulating Agents | This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|
|
| L03 - Immunostimulants | Immunosuppressants, see L04A.
|
|
| L03A - Immunostimulants | Levamisole, which also affects the immune response, is classified in P02CE.
|
|
| L03AC - Interleukins | | | The DDD for aldesleukin is based on the use of 5 vials (6.5 mg) per treatment cycle of 33 days.
|
|
|
